In addition, the mammalian target of rapamycin (mTOR) positively regulates glycolysis in tumor-infiltrating M-MDSCs, accompanied by strong immunosuppressive activity, which can be counteracted by treatment with rapamycin (RPM) [49,50]. Here, MTOR is linked to neoplasm.